Chapter 1. Introduction
1.1. Report description and scope
1.2. Research scope
1.3. Research methodology
1.3.1. Market research process
1.3.2. Market research methodology
Chapter 2. Executive Summary
2.1. Global melanoma drugs market, 2016 2022 (USD Billion)
2.2. Global melanoma drugs market : Snapshot
Chapter 3. Melanoma drugs Market Dynamics
3.1. Introduction
3.2. Market drivers
3.2.1. Global melanoma drugs market drivers: Impact analysis
3.2.2. Rising incidences of target disease
3.2.3. Development of novel agents and combination therapies
3.3. Market restraints
3.3.1. Global melanoma drugs market restraints: Impact analysis
3.3.2. High price of combination therapies and clinical trials
3.4. Opportunities
3.4.1. Increasing focus on targeted therapy
3.5. Porters five forces analysis
3.5.1. Bargaining power of suppliers
3.5.2. Bargaining power of buyers
3.5.3. Threat from new entrants
3.5.4. Threat from new substitutes
3.5.5. Degree of competition
3.6. Market attractiveness analysis
3.6.1. Market attractiveness analysis, by therapy segment
3.6.2. Market attractiveness analysis, by regional segment
Chapter 4. Global Melanoma drugs Market Competitive Landscape
4.1. Company Market Share Analysis
4.1.1. Global melanoma drugs market: company market share, 2015
4.2. Strategic Development
4.2.1. Acquisitions Mergers
4.2.2. New Therapy Launch
4.2.3. Agreements, Partnerships, Collaborations and Joint Ventures
4.2.4. Research and Development, Therapy and Regional Expansion
4.3. Price Trend Analysis
4.4. Therapy Portfolio
4.5. Patent Analysis (2011-2016)
4.5.1. Patent Trend
4.5.2. Patent Share by company
4.5.3. By Region
Chapter 5. Global Melanoma drugs Market Therapy Segment Analysis
5.1. Global melanoma drugs market: Therapy overview
5.1.1. Global melanoma drugs market revenue share, by Therapy, 2016 and 2022
5.2. Chemotherapy
5.2.1. Global Chemotherapy market , 2014 2022(USD Billion)
5.3. Immunotherapy
5.3.1. Global Immunotherapy market , 2014 2022(USD Billion)
5.4. Targeted Therapy
5.4.1. Global Targeted Therapy market , 2014 2022(USD Billion)
Chapter 6. Global Melanoma drugs Market Regional Segment Analysis
6.1. Global melanoma drugs market: Regional overview
6.1.1. Global melanoma drugs market revenue share, by region, 2014 and 2022
6.2. North America
6.2.1. North America melanoma drugs market revenue, by Therapy, 2014 2022(USD Billion)
6.2.2. U.S.
6.2.2.1. U.S. melanoma drugs market revenue, by Therapy, 2014 2022(USD Billion)
6.3. Europe
6.3.1. Europe melanoma drugs market revenue, by Therapy, 2014 2022(USD Billion)
6.3.2. Germany
6.3.2.1. Germany melanoma drugs market revenue, by Therapy, 2014 2022(USD Billion)
6.3.3. France
6.3.3.1. France melanoma drugs market revenue, by Therapy, 2014 2022(USD Billion)
6.3.4. UK
6.3.4.1. UK melanoma drugs market revenue, by Therapy, 2014 2022(USD Billion)
6.4. Asia Pacific
6.4.1. Asia Pacific melanoma drugs market revenue, by Therapy, 2014 2022, (USD Billion)
6.4.2. China
6.4.2.1. China melanoma drugs market revenue, by Therapy, 2014 2022(USD Billion)
6.4.3. Japan
6.4.3.1. Japan melanoma drugs market revenue, by Therapy, 2014 2022(USD Billion)
6.4.4. India
6.4.4.1. India melanoma drugs market revenue, by Therapy, 2014 2022(USD Billion)
6.5. Latin America
6.5.1. Latin America melanoma drugs market revenue, by Therapy, 2014 2022(USD Billion)
6.5.2. Brazil
6.5.2.1. Brazil melanoma drugs market revenue, by Therapy, 2014 2022(USD Billion)
6.6. Middle East and Africa
6.6.1. Middle East and Africa melanoma drugs market revenue, by Therapy, 2014 2022 (USD Billion)
Chapter 7. Company Profile
7.1. Amgen
7.1.1. Overview
7.1.2. Financials
7.1.3. Therapy portfolio
7.1.4. Business strategy
7.1.5. Recent developments
7.2. Bristol-Myers Squibb
7.2.1. Overview
7.2.2. Financials
7.2.3. Therapy portfolio
7.2.4. Business strategy
7.2.5. Recent developments
7.3. Hoffmann-La Roche Ltd
7.3.1. Overview
7.3.2. Financials
7.3.3. Therapy portfolio
7.3.4. Business strategy
7.3.5. Recent developments
7.4. Genentech Inc.,
7.4.1. Overview
7.4.2. Financials
7.4.3. Therapy portfolio
7.4.4. Business strategy
7.4.5. Recent developments
7.5. Janssen Biotech, Inc.
7.5.1. Overview
7.5.2. Financials
7.5.3. Therapy portfolio
7.5.4. Business strategy
7.5.5. Recent developments
7.6. Novartis International AG.
7.6.1. Overview
7.6.2. Financials
7.6.3. Therapy portfolio
7.6.4. Business strategy
7.6.5. Recent developments
7.7. Pfizer
7.7.1. Overview
7.7.2. Financials
7.7.3. Therapy portfolio
7.7.4. Business strategy
7.7.5. Recent developments
7.8. Sanofi
7.8.1. Overview
7.8.2. Financials
7.8.3. Therapy portfolio
7.8.4. Business strategy
7.8.5. Recent developments
7.9. Takeda Pharmaceutical Company Limited
7.9.1. Overview
7.9.2. Financials
7.9.3. Therapy portfolio
7.9.4. Business strategy
7.9.5. Recent developments
7.10. Teva Pharmaceuticals
7.10.1. Overview
7.10.2. Financials
7.10.3. Therapy portfolio
7.10.4. Business strategy
7.10.5. Recent developments